Report: Screening programs in Italy (Italy): Difference between revisions
(Created page with "{{#subobject:Screening programs in Italy |dct:title=Screening programs in Italy |datatype=policymaking }} '''Sponsor, manager or home institution:''' Osservatorio Nazionale Screening; Ministero della Salute. '''Primary purpose:''' Assesses annual cancer screening programs in Italy, indicating substantial participation in mammography and cervical screenings, significant progress in colorectal screening, and disparities in coverage between regions. '''Type of informat...") |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | {{forpolicymakers}} | ||
Go back to [[Italy]] page | |||
'''Sponsor, manager or home institution:''' Osservatorio Nazionale Screening; Ministero della Salute. | '''Sponsor, manager or home institution:''' Osservatorio Nazionale Screening; Ministero della Salute. | ||
Revision as of 15:41, 4 December 2023
Go back to Italy page
Sponsor, manager or home institution: Osservatorio Nazionale Screening; Ministero della Salute.
Primary purpose: Assesses annual cancer screening programs in Italy, indicating substantial participation in mammography and cervical screenings, significant progress in colorectal screening, and disparities in coverage between regions.
Type of information: Effective extent of mammography, cervical and colorectal screening; Participation (%) in screenings according to the country of origin; Waiting times; Invitations; Availability of pre-operative diagnosis; Conservative surgery; Total number of persons invited Number of persons participating in the invitation; Acceptance of the invitation; Number of persons examined in the period; Proportion of persons recalled for further investigation; Benign biopsies; Cancer identification rate; Invasive cancer identification rate; Percentage of conservative surgical treatment in invasive tumors; Mammography performed within the last 2 years; Fecal occult blood test programs - Main results in the two-year period; Programs with Rectosigmoidoscopy; Examination for the prevention of colorectal cancer in the recommended times (%) persons; Lesions with CIN2+ histology identified; Introduction of the human papilloma virus (Hpv) test as a screening test; Preventive test coverage in the last 3 years.
Data level: National and regional level.
Access to information: Access Information [1].